BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Feb 2025 07:00:08 By Nasdaq GlobeNewswire

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

10 Jan 2025 07:00:30 By Nasdaq GlobeNewswire

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

07 Jan 2025 07:00:57 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jan 2025 07:00:46 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Dec 2024 16:15:10 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

06 Nov 2024 07:00:53 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Nov 2024 07:00:47 By Nasdaq GlobeNewswire

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

04 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

24 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

BioCryst to Report Third Quarter 2024 Financial Results on November 4

21 Oct 2024 07:00:23 By Nasdaq GlobeNewswire

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

14 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

10 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Oct 2024 07:00:53 By Nasdaq GlobeNewswire

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

02 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

30 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

06 Sep 2024 02:00:11 By Nasdaq GlobeNewswire

BioCryst Appoints Dr. Donald Fong Chief Medical Officer

05 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Sep 2024 07:00:46 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

22 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

05 Aug 2024 07:00:24 By Nasdaq GlobeNewswire